ICP Building Solutions Group Acquires Gardner-Gibson, a Leading Supplier of Roofing Products and Driveway Sealers
5.1.2021 00:05:00 EET | Business Wire | Press release
Innovative Chemical Products (“ICP Group” or “ICP”), a leader in specialty coatings, adhesives and building envelope solutions, announced today that it has acquired Gardner-Gibson and Sun Coatings (“Gardner-Gibson”), a leading manufacturer of liquid-applied roof coatings, roofing products, driveway sealers and specialty paints primarily serving professional contractors for commercial and residential applications. The acquisition builds upon ICP Group’s extensive line of building solutions and global distribution network and creates one of the largest privately held coatings and adhesives companies in North America.
“The Gardner-Gibson acquisition and combination with ICP Group will strengthen the product offerings and distribution network for both companies,” said Doug Mattscheck, CEO, ICP Group. “We were strong individually and will be even stronger together as we enhance our portfolio of coatings, adhesives and building envelope solutions. ICP Group welcomes the Gardner-Gibson employees to the ICP family and looks forward to supporting the continued growth of the combined businesses.”
Based in Tampa, Florida, Gardner-Gibson is one of the leading providers of liquid-applied roof coatings, roofing products, driveway sealers and specialty paint, and is recognized for its industry-leading brands. With manufacturing and distribution facilities across the U.S. and Canada, Gardner-Gibson’s products are sold in leading retailers and building supply distributors under the Gardner®, Black Jack®, APOC® and Dyco® brands.
The integration of Gardner-Gibson into ICP’s Building Solutions Group unites premier brands to offer a wide range of products for roofing, building envelope and flooring applications primarily serving commercial facilities and repair and maintenance applications.
“ICP Group has the infrastructure, networks and experience to take Gardner-Gibson to new levels of success,” said Sean Hyer, CEO, Gardner-Gibson. “We’re looking forward to working together and delivering more value to our customers, retail partners and distributors for years to come. It’s an exciting time to be at Gardner-Gibson as we enter this new era of innovation and product expansion with ICP.”
Lazard Middle Market served as financial advisor and Foley & Lardner LLP served as legal counsel to Gardner-Gibson on the transaction. Kirkland & Ellis LLP served as legal counsel to ICP Group on the transaction, and J.P. Morgan, BMO, Antares Capital and Goldman Sachs provided the financing.
For more information about ICP, visit www.icpgroup.com.
The ICP Group is a portfolio company of Audax Private Equity.
About ICP
Innovative Chemical Products (“ICP Group”) is a leading manufacturer of specialty coatings, adhesives and sealants. With operations headquartered in Andover, Massachusetts, and multiple manufacturing facilities around the world, ICP serves multiple end markets, including building envelope, packaging and specialty print. ICP Group is privately held and manufactures products under several recognized specialty groups. For more information, visit www.icpgroup.com.
About ICP Building Solutions Group
ICP Building Solutions Group is the foremost supplier of professional coatings, adhesives and sealants for building envelope and flooring needs. Comprising dozens of industry-leading brands across numerous industries and applications, ICP Building Solutions Group offers the industry’s most comprehensive portfolios to building professionals all over the globe. For more information, visit www.icpgroup.com.
About Gardner-Gibson
Gardner-Gibson, Inc., serves professional contractors and DIYers as a full-line manufacturer of roof, driveway and waterproofing coatings, caulks and sealants. Headquartered in Tampa, Florida, Gardner-Gibson operates manufacturing and distribution facilities across North America. For more information about Gardner-Gibson products, as well as project resources and application tips, visit www.gardner-gibson.com/.
About Audax Private Equity
Audax Group is a leading alternative investment manager with offices in Boston, New York and San Francisco. Since its founding in 1999, the firm has raised over $27 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $6 billion in more than 135 platforms and over 900 add-on companies, and is currently investing out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations and significantly increase equity value. With more than 250 employees and over 100 investment professionals, the firm is a leading capital partner for North American middle-market companies. For more information, visit the Audax Group website, www.audaxgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005795/en/
Contact information
Bridget Hagan
bridget.hagan@akhia.com
330.463.5650
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom